Crossmark

Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial

Crossref DOI link: https://doi.org/10.1136/svn-2018-000221

Published Online: 2019-04-22

Published Print: 2019-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Xu, Jie https://orcid.org/0000-0002-8320-218X
Wang, Yilong

Wang, Anxin https://orcid.org/0000-0003-4351-2877
Gao, Zhiqiang

Gao, Xiaoping

Chen, Huisheng https://orcid.org/0000-0002-8490-9435
Zhou, Junshan

Zhao, Xingquan

Wang, Yongjun https://orcid.org/0000-0002-9976-2341
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01929096 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial ^(Results)
https://doi.org/10.1136/svn-2018-000221

nct01929096 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial ^(Results)
https://doi.org/10.1136/svn-2018-000221
Funding

Funding for this research was provided by:

Simcere Pharmaceutical Group supported the present study

Document is current

Any future updates will be listed below